Evidence of differential effects of vitamin D receptor variants on epithelial ovarian cancer risk by predicted vitamin D status

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Prescott, Jennifer ^a,b   Bertrand, Kimberly A ^a,b   Reid, Brett M ^c   Permuth Wey, Jennifer ^c   de Vivo, Immaculata ^a,b   Cramer, Daniel W ^a,b   Terry, Kathryn L ^a,b   Tworoger, Shelley S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Haplotype; Heterogeneity; Ovarian cancer; Polymorphism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CYTOCHROME P450; GENOMIC DNA; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CARCINOMA; PHENOTYPE; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUESTIONNAIRE; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE TUBE LIGATION; VARIABLE NUMBER OF TANDEM REPEAT; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

EID: 84907813298     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00286     Document Type: Article

References (65)

1. Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs (1993) 4(2):201-8.
2. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer (2000) 86(1):40-6. doi:10.1002/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO;2-E [pii]
3. Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem (2004) 279(24):25260-7. doi:10.1074/jbc.M311052200 M311052200 [pii]
4. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem (2004) 279(51):53213-21. doi:M410395200 [pii] 10.1074/jbc.M410395200
5. Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, et al. Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Invest New Drugs (2010) 28(5):543-53. doi:10.1007/s10637-009-9284-y
6. Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, et al. PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Genes Cancer (2013) 4(11-12):524-34. doi:10.1177/1947601913507575
7. Saunders DE, Christensen C, Lawrence WD, Malviya VK, Malone JM, Williams JR, et al. Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol (1992) 44(2):131-6.
8. Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res (2002) 22(4):2261-7.
9. Thill M, Fischer D, Kelling K, Hoellen F, Dittmer C, Hornemann A, et al. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol (2010) 121(1-2):387-90. doi:S0960-0760(10)00148-2 [pii] 10.1016/j.jsbmb.2010.03.049
10. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res (2003) 164239-46.
11. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol (2006) 57(2):234-40. doi:10.1007/s00280-005-0059-7
12. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol (1994) 23(6):1133-6.
13. Garland CF, Mohr SB, Gorham ED, Grant WB, Garland FC. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med (2006) 31(6):512-4. doi:S0749-3797(06)00328-X [pii] 10.1016/j.amepre.2006.08.018
14. Grant WB. The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival. Anticancer Res (2006) 26(4A):2605-14.
15. Grant WB. A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: additional evidence that solar ultraviolet-B irradiance reduces the risk of internal cancers. J Steroid Biochem Mol Biol (2007) 103(3-5):668-74. doi:S0960-0760(06)00405-5 [pii] 10.1016/j.jsbmb.2006.12.030
16. Grant WB. An ecological study of cancer mortality rates in the United States with respect to solar ultraviolet-B doses, smoking, alcohol consumption and urban/rural residence. Dermatoendocrinol (2010) 2(2):68-76. doi:10.4161/derm.2.2.13812
17. Tran B, Jordan SJ, Lucas R, Webb PM, Neale R. Association between ambient ultraviolet radiation and risk of epithelial ovarian cancer. Cancer Prev Res (Phila) (2012) 5(11):1330-6. doi:1940-6207.CAPR-12-0279 [pii] 10.1158/1940-6207.CAPR-12-0279
18. Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control (2012) 23(12):1985-94. doi:10.1007/s10552-012-0076-x
19. Lin SW, Wheeler DC, Park Y, Cahoon EK, Hollenbeck AR, Freedman DM, et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer (2012) 131(6):E1015-23. doi:10.1002/ijc.27619
20. Prescott J, Bertrand KA, Poole EM, Rosner BA, Tworoger SS. Surrogates of long-term vitamin d exposure and ovarian cancer risk in two prospective cohort studies. Cancers (Basel) (2013) 5(4):1577-600. doi:10.3390/cancers5041577
21. Merritt MA, Cramer DW, Vitonis AF, Titus LJ, Terry KL. Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes. Int J Cancer (2013) 132(5):1114- doi:10.1002/ijc.27701
22. Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol (2002) 156(2):148-57.
23. Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol (1999) 149(1):21-31.
24. Koralek DO, Bertone-Johnson ER, Leitzmann MF, Sturgeon SR, Lacey JV, Jr., Schairer C, et al. Relationship between calcium, lactose, vitamin D, and dairy products and ovarian cancer. Nutr Cancer (2006) 56(1):22-30. doi:10.1207/s15327914nc5601_4
25. Bidoli E, La Vecchia C, Talamini R, Negri E, Parpinel M, Conti E, et al. Micronutrients and ovarian cancer: a case-control study in Italy. Ann Oncol (2001) 12(11):1589-93.
26. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology (2002) 63(2):151-7. doi:ocl63151 [pii]
27. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, et al. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev (2006) 15(2):364-72. doi:15/2/364 [pii] 10.1158/1055-9965.EPI-05-0484
28. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 172(1):70-80. doi:kwq118 [pii] 10.1093/aje/kwq118
29. Toriola AT, Surcel HM, Agborsangaya C, Grankvist K, Tuohimaa P, Toniolo P, et al. Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur J Cancer (2010) 46(2):364-9. doi:S0959-8049(09)00584-X [pii] 10.1016/j.ejca.2009.08.002
30. Toriola AT, Surcel HM, Calypse A, Grankvist K, Luostarinen T, Lukanova A, et al. Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer (2010) 46(15):2799-805. doi:S0959-8049(10)00443-0 [pii] 10.1016/j.ejca.2010.05.019
31. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 41(9):996-1000. doi:ng.424 [pii] 10.1038/ng.424
32. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 42(10):874-9. doi:10.1038/ng.668
33. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 42(10):880-4. doi:10.1038/ng.666
34. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 45(4):362-70, 70e1-2. doi:10.1038/ng.2564
35. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene (2004) 338(2):143-56. doi:10.1016/j.gene.2004.05.014
36. Xu H, Li S, Qiu JQ, Gao XL, Zhang P, Yang YX. The VDR gene FokI polymorphism and ovarian cancer risk. Tumour Biol (2013) 34(6):3309-16. doi:10.1007/s13277-013-0826-8
37. Liu Y, Li C, Chen P, Li X, Li M, Guo H, et al. Polymorphisms in the vitamin D Receptor VDR) and the risk of ovarian cancer: a meta-analysis. PLoS One (2013) 8(6):e66716. doi:10.1371/journal.pone.0066716 PONE-D-13-13238 [pii]
38. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate (2007) 67(9):911-23. doi:10.1002/pros.20570
39. Rukin NJ, Luscombe C, Moon S, Bodiwala D, Liu S, Saxby MF, et al. Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene. Cancer Lett (2007) 247(2):328-35. doi:10.1016/j.canlet.2006.05.012
40. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis (2009) 30(5):769-76. doi:10.1093/carcin/bgp055
41. Mandelcorn-Monson R, Marrett L, Kricker A, Armstrong BK, Orlow I, Goumas C, et al. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiol (2011) 35(6):e105-10. doi:10.1016/j.canep.2011.03.003
42. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 376(9736):180-8. doi:10.1016/S0140-6736(10)60588-0
43. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 19(13):2739- doi:10.1093/hmg/ddq155
44. Lasky-Su J, Lange N, Brehm JM, Damask A, Soto-Quiros M, Avila L, et al. Genome-wide association analysis of circulating vitamin D levels in children with asthma. Hum Genet (2012) 131(9):1495-505. doi:10.1007/s00439-012-1185-z
45. Adams JS, Clemens TL, Parrish JA, Holick MF. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med (1982) 306(12):722- doi:10.1056/NEJM198203253061206
46. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol (2005) 161(5):442-51. doi:161/5/442 [pii] 10.1093/aje/kwi064
47. Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL. Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer (2012) 131(4):E518-29. doi:10.1002/ijc.26455
48. Bertrand KA, Giovannucci E, Liu Y, Malspeis S, Eliassen AH, Wu K, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr (2012) 108(10):1889-96. doi:S0007114511007409 [pii] 10.1017/S0007114511007409
49. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr (1997) 65(4 Suppl):1220S-8S; discussion 9S-31S.
50. John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol (2007) 166(12):1409-19. doi:10.1093/aje/kwm259
51. Kidd LC, Paltoo DN, Wang S, Chen W, Akereyeni F, Isaacs W, et al. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate (2005) 64(3):272-82. doi:10.1002/pros.20204
52. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res (2009) 69(5):1885-91. doi:10.1158/0008-5472.CAN-08-3515
53. Hollis BW. Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol (1997) 282174-86. doi:S0076-6879(97)82106-4 [pii]
54. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered (2002) 53(2):79-91.
55. Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol (2005) 28(3):261-72. doi:10.1002/gepi.20061
56. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet (1993) 92(2):183-8.
57. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials (1986) 7(3):177- doi:0197-2456(86)90046-2 [pii]
58. Gauderman W, Morrison J. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe. 2006.
59. Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med (2009) 169(6):626-32. doi:10.1001/archinternmed.2008.604
60. Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev (2008) 66(10 Suppl 2):S153-64. doi:10.1111/j.1753-4887.2008.00100.x
61. Malinen M, Saramaki A, Ropponen A, Degenhardt T, Vaisanen S, Carlberg C. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res (2008) 36(1):121-32. doi:10.1093/nar/gkm913
62. Colin EM, Weel AE, Uitterlinden AG, Buurman CJ, Birkenhager JC, Pols HA, et al. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) (2000) 52(2):211-6.
63. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet (1986) 72(4):281-93.
64. Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl (1995) 23200-7.
65. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res (2001) 125(1-2):279-84. doi:S0166-4328(01)00297-2 [pii]